ClinicalTrials.gg
Active, not recruitingNCT04516070Updated Sep 14, 2026

Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis

A Phase 2 interventional study of Questionnaire Administration and Stereotactic Radiosurgery in Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain and Stage IV Lung Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Small Cell Lung Carcinoma by M.D. Anderson Cancer Center — none open to participants now, 2 under way, none of them phase 3. Small Cell Lung Carcinoma · M.D. Anderson Cancer Center.

Enrollment
4th of 10
55 · median 40
Started
2020
the only one that year
Phase 2
5 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Small Cell Lung Carcinoma by M.D. Anderson Cancer Center, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 2, and was the 9th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

None of the 11 studies in Small Cell Lung Carcinoma by M.D. Anderson Cancer Center is open now. The open studies under Small Cell Lung Carcinoma, anywhere →

Where they have run

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Small Cell Lung Carcinoma by M.D. Anderson Cancer Center as a file.
02

Study summary

This phase II trial investigates how stereotactic radiosurgery affects brain functions while treating patients with small cell lung cancer that has spread to the brain (brain metastasis). Standard of care treatment consists of whole brain radiation therapy, which targets the entire brain, and may result in side effects affecting the nervous system. Stereotactic radiosurgery only targets areas of the brain that are suspected to be affected by the disease. The purpose of this trial is to learn if and how patients' brain functions are affected by the use of stereotactic radiosurgery rather than whole brain radiation therapy in managing brain metastasis caused by small cell lung cancer. Stereotactic radiosurgery may help patients avoid nervous system side effects caused by whole brain radiation therapy.

Read the detailed description

PRIMARY OBJECTIVE:

I. To estimate the cognitive decline rate at 3 months.

SECONDARY OBJECTIVES:

I. To examine cognitive decline rate on each individual cognitive test at each time point.

II. To examine cognitive decline rates using reliable change index methodology. III. To report the overall survival of patients (death due to any cause) of patients receiving stereotactic radiosurgery (SRS) for small cell lung cancer (SCLC) brain metastasis.

IV. To report rates of local tumor control (of the treated lesions) in the brain post-treatment, as dictated by magnetic resonance imaging (MRI) surveillance schedule above.

V. To report distant tumor control in the brain (of non-treated lesions) post-treatment, as dictated by MRI surveillance schedule above.

VI. To report time elapsed from SRS to whole brain radiation therapy (WBRT). VII. To report rate of intracranial toxicity of SRS in the setting of prior WBRT.

VIII. To report rates of intracranial toxicity of concurrent atezolizumab with SRS.

IX. To determine rates of systemic and intracranial disease control (time to progression) in those who are treated concurrently with atezolizumab and SRS.

X. To determine the rates of SCLC-specific survival. XI. To assess the pre-treatment factors and baseline characteristics in the predictive determination of local control, intracranial control, systemic control, and neurocognitive outcomes.

XII. To assess the correlation between number of lesions and total volume of intracranial disease and neurocognitive outcome.

XIII. To document post-treatment intracranial toxicity profile in patients after SRS.

CORRELATIVE OBJECTIVE:

I. Cerebral spinal fluid (CSF) biomarkers.

OUTLINE:

Patients undergo SRS in the absence of disease progression or unacceptable toxicity. Patients whose disease progresses may be treated with additional courses of SRS per physician discretion.

After completion of study treatment, patients are followed up at 1, 3, 6, 9, 12, 16, 20, 24, 30, and 36 months after SRS.

03

Conditions studied

  • Metastatic Lung Small Cell Carcinoma
  • Metastatic Malignant Neoplasm in the Brain
  • Stage IV Lung Cancer AJCC v8
  • Stage IVA Lung Cancer AJCC v8
  • Stage IVB Lung Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have (ECOG) =\< 3
  • All patients must have histologic evidence suggesting small cell lung cancer. Histologic confirmation may be from the primary tumor site, or from another site (systemic lymph node, etc.). Cytology-alone is not an acceptable method of diagnosis.
  • Patient has 10 or less on contrast-enhanced brain MRI scan obtained no greater than 6 weeks prior to study registration. of brain metastasis is not required. A patient may be enrolled with zero brain metastasis assuming that the SRS is to be directed at the post-operative surgical cavity of a resected metastasis.
  • Patients must be eligible to have all lesions treated with stereotactic radiosurgery as determined by the study radiation oncologist
  • Patients must sign indicating that they are aware of the nature of this study in keeping with the policies of the hospital
  • Patients should have normal coagulation [ (INR) \< 1.3]. within 28 days of enrollment.
  • Patient's primary language is English
  • No prior radiation therapy to the brain, including WBRT, PCI, or SRS
  • Performance Status Assessment
  • Standard ECOG performance status assessment will be used and determined by the treating physician

Exclusion criteria

Exclusion Criteria:

  • Patients are excluded if they have a history of cancer in addition to small cell or a history of uncontrolled non-metastatic cancer. Patients with localized squamous cell carcinoma and/or basal cell carcinoma are not excluded
  • Patients are excluded if there is radiographic evidence of
  • Patients are excluded if there are malignant cells identified in the CSF on cytologic examination
  • Patients are not excluded for circulating tumor deoxyribonucleic acid (DNA) (ctDNA) found in the CSF
  • Female patients of childbearing age are excluded if they are pregnant as determined with a urine or serum beta human chorionic gonadotropin (HCG) no greater than 14 days prior to study registration, or breast-feeding
  • Patients are excluded if they are unable to obtain an MRI scan for any other reason, including gadolinium allergy
  • Patients are excluded with medical history of a psychiatric or neurologic illness, or other comorbidities believed to affect cognitive function. Subjects with neurocognitive deficit related to are an exception to this criterion and may qualify for the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Treatment (SRS)

    Patients undergo SRS in the absence of disease progression or unacceptable toxicity. Patients whose disease progresses may be treated with additional courses of SRS per physician discretion.

    Other: Questionnaire Administration · Radiation: Stereotactic Radiosurgery

Interventions

  • OtherQuestionnaire Administration

    Ancillary studies

  • RadiationStereotactic Radiosurgery

    Undergo SRS

    Also known as: Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery

06

What researchers measure

Primary outcomes

  1. Cognitive decline

    Will be defined as a decline of \>= 1 standard deviation from baseline on at least 1 of the 5 cognitive tests. Will be estimated along with the 95% confidence interval. For patients with or without prior radiation therapy to the central nervous system, the cognitive decline rate will also be estimated respectively. Fisher exact test will be used to compare the neurocognitive decline rate at 3 month post-SRS in subgroups (e.g. prior therapy difference).

    Time frame: At 3 months post-stereotactic radiosurgery (SRS)

  2. Incidence of adverse events

    All toxicities will be assessed with National Cancer Institute predefined Common Terminology Criteria for Adverse Events version 5.

    Time frame: Up to 36 months

Secondary outcomes

  1. Cognitive decline

    Will use descriptive statistics and boxplots to summarize and illustrate the neurocognitive function score at each assessment time.

    Time frame: Up to 36 months

  2. Change in neurocognitive score

    Will summarize and illustrate the change from baseline in neurocognitive score. Will also model the cognitive data with mixed effects regression including baseline neurocognitive scores, time, and number of lesions, extra-cranial disease, and a patient specific random effect.

    Time frame: Baseline, up to 36 months

  3. Overall survival

    Will be estimated using the product-limit estimator of Kaplan and Meier, and log-rank test will be used for comparison of neurocognitive decline rate in subgroups (e.g. prior radiation treatment status). Cox proportional hazards regression will be used to model time to event survival as a function of age, performance status, extra-cranial disease, and other factors.

    Time frame: Time from SRS until death or last follow-up, assessed up to 36 months

  4. Small cell lung cancer (SCLC)-specific survival

    Will be estimated using the product-limit estimator of Kaplan and Meier, and log-rank test will be used for comparison of neurocognitive decline rate in subgroups (e.g. prior radiation treatment status). Cox proportional hazards regression will be used to model time to event survival as a function of age, performance status, extra-cranial disease, and other factors.

    Time frame: Time from SRS till SCLC-related death or last follow-up, assessed up to 36 months

  5. Time to neurocognitive decline

    Will be estimated using the product-limit estimator of Kaplan and Meier, and log-rank test will be used for comparison of neurocognitive decline rate in subgroups (e.g. prior radiation treatment status). Cox proportional hazards regression will be used to model time to event survival as a function of age, performance status, extra-cranial disease, and other factors.

    Time frame: Time from date of SRS till the cognitive decline, assessed up to 36 months

  6. Time duration from SRS to whole brain radiation therapy (WBRT)

    Will be estimated using the product-limit estimator of Kaplan and Meier, and log-rank test will be used for comparison of neurocognitive decline rate in subgroups (e.g. prior radiation treatment status). Cox proportional hazards regression will be used to model time to event survival as a function of age, performance status, extra-cranial disease, and other factors.

    Time frame: Time from SRS to the start of WBRT treatment, assessed up to 36 months

  7. Local tumor control rates

    Will be estimated along with 95% confidence intervals. The association between the control rate and patient characteristics including pre-treatment factors (e.g. number of lesions) will be evaluated using Wilcoxon rank sum test or Fisher exact test. Logistic regression will be used to assess different patient clinical factor effect on the control rate.

    Time frame: Up to 36 months

  8. Distant tumor control rate

    Will be estimated along with 95% confidence intervals. The association between the control rate and patient characteristics including pre-treatment factors (e.g. number of lesions) will be evaluated using Wilcoxon rank sum test or Fisher exact test. Logistic regression will be used to assess different patient clinical factor effect on the control rate.

    Time frame: Up to 36 months

  9. Rate of systemic and intracranial disease control rate

    Will be estimated along with 95% confidence intervals. The association between the control rate and patient characteristics including pre-treatment factors (e.g. number of lesions) will be evaluated using Wilcoxon rank sum test or Fisher exact test. Logistic regression will be used to assess different patient clinical factor effect on the control rate.

    Time frame: Up to 36 months

  10. Response to SRS therapy

    Will be determined by the radiology report. Will be estimated along with 95% confidence intervals. The association between the control rate and patient characteristics including pre-treatment factors (e.g. number of lesions) will be evaluated using Wilcoxon rank sum test or Fisher exact test. Logistic regression will be used to assess different patient clinical factor effect on the control rate.

    Time frame: Up to 36 months

  11. Post-treatment intracranial toxicity profile

    Will be summarized and documented.

    Time frame: Up to 36 months

  12. Rate of intracranial toxicity of SRS in the setting of prior WBRT

    Will be summarized according to intensity and treatment relationship, and categorized by System Organ Class.

    Time frame: Up to 36 months

  13. Rate of intracranial toxicity concurrent atezolizumab with SRS

    Will be summarized according to intensity and treatment relationship, and categorized by System Organ Class.

    Time frame: Up to 36 months

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Dec 2026, 76 months after the start.

Of 150 non-industry phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 76 months is above that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2020
First posted
Aug 17, 2020
StartActual
Aug 28, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04516070
Responsible party
Sponsor
First posted
Aug 17, 2020
Start date
Aug 28, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 14, 2026

Study contacts

Jing Li
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion